On the other hand, recent advances in our understanding of genomic alterations in meningioma have resulted in the introduction of potential therapeutic targets, such as mammalian target of rapamycin (mTOR), vascular endothelial growth factor receptor, the hedgehog pathway, focal adhesion kinase, AKT, and cyclin-dependent kinase [5]. This evidence concerns the gene MTOR and meningioma.